Has a Cancer Vaccine Really Been Developed? A New Step in Cancer Treatment

A question many people are asking these days: is there finally a vaccine for cancer?

The short answer has two parts. Yes, a new treatment has shown results in a type of skin cancer (melanoma), and those results come from a phase 3 trial, the largest stage of clinical testing. And no, this treatment is not yet approved or available outside clinical trials, and it has not been studied in gynecologic cancers either.

What makes this news worth understanding is where it shows medicine is heading: a treatment built from the genetics of one specific patient’s tumor, for that one person only.

To most people, a vaccine is something given before an illness. For example, the HPV (human papillomavirus) vaccine is given to healthy people to help prevent infection with the virus, and so to help prevent a large share of cervical cancers.

But the vaccine in this news belongs to a different category.

The US National Cancer Institute defines the two separately: cancer treatment vaccines are designed for people who already have cancer, and they target the cancer cells themselves rather than whatever caused the cancer.

In the trial behind this news, the vaccine was used after surgery had completely removed the tumor. In other words, it was given to patients whose tumor had been fully removed but who had a high risk of the cancer coming back.

The vaccine is meant to train the immune system so that, if any cancer cells are left in the body, the immune system recognizes and clears them.

Making a personalized vaccine takes four steps:

1. A tissue sample is taken from the patient’s own tumor.
2. The tumor’s genetic code is sequenced to find the mutations (changes) that exist only in that patient’s cancer cells.
3. Based on those mutations, a strand of mRNA (a set of genetic instructions) is made that codes for up to 34 markers specific to that tumor.
4. The finished vaccine is injected so the immune system learns to target those markers.

This is the main difference from conventional drug-making: what stays the same is the process, not the drug. One process produces a different product for each patient.

This vaccine is also not used on its own. It is given together with an immunotherapy drug from the immune checkpoint inhibitor family, which has itself been officially approved since 2019 (and since 2021 for earlier stages as well) to lower the risk of melanoma coming back after surgery.

The division of labor between the two is simple: the immunotherapy drug releases the brakes on the immune system, and the vaccine shows it what to attack.

The first study: a small trial with five-year follow-up. A phase 2 study was done in 157 patients with high-risk melanoma that had been removed by surgery.

That study had two clear limitations, though: the number of patients was small, and it was not blinded (patients and doctors knew who was getting the vaccine).

In clinical research, results from a small, unblinded study do not carry the same weight as results from a large, double-blind one (where neither patients nor doctors know who gets what). That is why the second study matters.

The second study: the large trial. This trial included 1,137 patients with high-risk stage IIB to IV melanoma whose tumors had been completely removed. The design was double-blind, and treatment lasted about one year.

The result, announced by the companies developing the vaccine: the combination did better on its primary measure and its key secondary measure. People went longer without the cancer coming back, and longer without it spreading to distant parts of the body. The companies also said that no new safety concerns were seen. The full results, presented in October 2026, confirmed this: the risk of the cancer coming back or death was about 42% lower.

It helps to keep three points separate.

In some gynecologic cancers, the molecular features of the tumor already play a part in choosing treatment today.

For example, in endometrial cancer the tumor’s DNA repair status can affect the choice of treatment, as can certain gene mutations in ovarian cancer treatment.

Immunotherapy drugs are also used, in specific situations and together with other treatments, for cervical cancer and endometrial cancer. This does not mean that the personalized vaccine in the news can be used for these cancers.

In cervical cancer, treatment vaccines follow a different path. Because the main cause of this cancer is a known virus (HPV), treatment vaccines target the virus’s own proteins instead of mutations specific to each tumor.

According to a scientific review published in April 2026, this is where the approach stands today: several treatment vaccines are in clinical trials, and some have shown promising results in precancerous changes, but none has yet been approved for treating cervical cancer.

The practical takeaway for today is clear. In gynecologic cancers, the only vaccine available right now with proven benefit is the preventive HPV vaccine, used alongside regular screening. That vaccine helps protect against infection; it does not take the place of treatment.

And one point that usually gets lost when this news is retold: personalized does not mean free of side effects.

In the same phase 2 study, the most common side effects reported were tiredness, pain at the injection site and chills, and immune-related side effects were roughly the same in both groups. The benefit seen was a lower rate of recurrence; it did not come with fewer side effects.

This news is a real step forward on the road to treating cancer, but it is not an available treatment. Its value is in showing that a treatment built on the genetics of each patient’s tumor can be made on a large scale.

The only vaccine available today in the field of gynecologic cancers is the preventive HPV vaccine. The “HPV vaccine and prevention” page explains what this vaccine does and what it does not do.